SEC EDGARSEP 151 min read$PHVS

Modig Berndt sold $90K of PHVS

Modig Berndt (Chief Executive Officer) sold 2,291 shares of Pharvaris N.V. (PHVS) at $39.40 on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Modig Berndt

Published Sep 15, 2026, 6:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 15, 2026, 6:20 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PHVS

Neutral

medium confidence

Mentioned

$PHVS

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PHVSNeutralLow

Why it matters

The CEO's sale via a pre‑arranged plan is a routine liquidity move; unlikely to drive major price change.

Market read

Provides fresh insider data for traders monitoring PHVS; limited broader market effect.

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 2/10Novelty 5/10Timing: post‑market 2026‑09‑14

Background

Form 4 filing reveals insider transaction for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PHVSNeutralMedium confidence

Context

CEO Modig Berndt sold 2,291 shares for $90,276 via a 10b5‑1 plan.

Expected impact

Potential short‑term downward pressure, likely limited to a few cents.

Evidence & confidence

The sale size is modest relative to holdings; market may view it as routine.

Market effects

Sector

Minimal impact on biotech sector; typical insider activity.

Regional

No significant regional effect.

Global

Limited to investors tracking PHVS.

Counterpoint

What could challenge this read

The sale could be a strategic tax‑loss harvest rather than a negative signal.

Key entities

Company
Pharvaris N.V.
Biotech firm listed on Nasdaq under ticker PHVS.
Person
Modig Berndt
Chief Executive Officer of Pharvaris.

Read at source ← All news

OCT 26

$PHVSHighAI 9/10

Bank of America backs Pharvaris on breakthrough for rare swelling disease

Bank of America upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing strong trial results for its HAE treatment drug, deucrictibant. The stock closed at $31.41 on Oct. 23. BofA sees substantial upside and notes positive feedback from doctors. The FDA decisions in 2027 could impact the stock.

finance.yahoo.com2 min

OCT 23

$PHVSMed

Pharvaris rises after BofA upgrades to Buy (PHVS:NASDAQ)

Pharvaris (PHVS) shares rose 3% premarket after BofA upgraded the stock to Buy from Neutral, citing its oral HAE potential. The brokerage kept its $44 price target. Pharvaris announced in September its.

seekingalpha.com1 min

OCT 23

$PHVSHigh

BofA upgrades Pharvaris stock rating on oral HAE treatment potential

BofA upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing potential in its oral HAE treatment. The stock trades at $30.68, up 10.6% in a week. Positive phase 3 data and strong analyst ratings highlight its prospects, despite risks like market adoption and competition.

investing.com1 min

OCT 9

$PHVSHighAI 9/10

Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027

Pharvaris (PHVS) reported that its Phase 3 study of deucrictibant XR for hereditary angioedema (HAE) met all endpoints, reducing attack rates by 83%. The company plans to file for FDA approval in H1 2027. PHVS stock closed at $31.12, up 0.58% in after-hours trading.

rttnews.com3 min

OCT 8

$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.

investing.com5 min